Dear Colleagues,

Twenty years after the groundbreaking "first-in-men case" performed by Professor Cribier, transcatheter aortic valve replacement (TAVR) has become more than a mere alternative to surgical aortic valve replacement (SAVR) for elderly and comorbid patients suffering from symptomatic severe aortic stenosis. In fact, TAVR has now emerged as the leading intervention worldwide.

Given the swift evolution of TAVR and the decreasing volume of SAVR procedures, substantial progress has been achieved in the past decade. These advancements encompass procedural innovations, including the emergence of alternative access sites, the minimization of access sites, the introduction of stroke prevention devices, and the development of post-procedural management strategies that entail the careful selection of suitable antithrombotic agents and determination of their optimal duration.

Important contemporary issues still remain in the current TAVR era, which include valve durability, valve thrombosis hemodynamics, future coronary access, etc.

It is my pleasure to announce that I will be serving as the Guess Editor for a Special Issue of the Journal of Clinical Medicine dedicated to “New Developments in Transcatheter Aortic Valve Replacement”. I believe you could make a relevant contribution based on the expertise of your team in this field.

The aim of this Special Issue is to provide clear, practical information to the clinician involved in the management of patients with aortic valve disease. In particular, the following aspects of the remaining challenges will be covered:

• Antithrombotic and antiplatelet strategies in TAVR;
• Updates on valve durability: pathophysiology and clinical impact;
• Valve thrombosis: pathophysiology, standardized definition, available data, and pharmacological prevention;
• Updates on coronary access: importance of commissural misalignment;
• Reduction in pacemaker implantation: strategies and clinical impact;
• Vascular access: towards a full percutaneous program–strategy and impact of vascular lithotripsy;
• Stroke: clinical impact, predictive factors, and prevention;
• Bleeding and TAVR: clinical impact, predictive factors, association with Heyde syndrome, and prevention;
• TAVR in pure aortic regurgitation;
• TAVR in moderate AS patients;
• New strategies to curb aortic valve disease progression: lithotripsy and pharmacological prevention;
• Heart failure readmission: pathophysiology, clinical impact, and pharmacological prevention.

I understand that as researchers, you receive numerous notifications to publish in special volumes from different journals and editorial boards. However, I would like to highlight the benefits of submitting your work to this Special Issue on “New Developments in Transcatheter Aortic Valve Replacement” that will be published by the Journal of Clinical Medicine (JCM):

• Broad readership: JCM has experienced substantial readership growth in recent years. In 2022, the journal received approximately 17 million paper views on its website. Over the past six months in 2023, the average monthly views have exceeded 2 million. This indicates that your research will have the opportunity to reach a wide and diverse audience, maximizing its impact.
• Citations and impact: JCM's current Impact Factor (IF) stands at 3.9, with a 5-Year Impact Factor of 4.1. Additionally, the CiteScore of the journal is 5.4.
• Social media coverage: JCM papers often receive substantial attention on social media platforms, extending the reach of your work beyond the academic sphere. As an added benefit, we encourage you to provide a graphical abstract, which enhances the visual impact of your submission and attracts attention from a wider audience.

I am excited to receive your valuable contribution to this Special Issue. If you have any questions or require further information, please do not hesitate to contact me. I look forward to the opportunity to showcase your research in JCM's Special Issue on “New Developments in Transcatheter Aortic Valve Replacement."

Dr. Olivier Morel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• transcatheter aortic valve replacement
• TAVR
• aortic valve disease